We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Halozyme Therapeutics, Inc. (HALO - Free Report) reported third-quarter 2020 earnings of 25 cents per share, beating the Zacks Consensus Estimate of 20 cents. The company had reported a loss of 17 cents in the year-ago quarter.
Total revenues increased 41.3% year over year to $65.3 million primarily due to milestone payments from Roche (RHHBY - Free Report) and argenx (ARGX - Free Report) . The top line also beat the Zacks Consensus Estimate of $60 million.
Shares of Halozyme were up 7.7% in after-market trading on Nov 2, following the earnings release. The stock has gained 83.8% so far this year compared with the industry’s 1% increase.
Quarterly Highlights
Halozyme’s top line comprises product sales, royalties and revenues under collaborative agreements.
Royalty revenues were $23.9 million in the third quarter, up 44.1% from the year-ago quarter mainly driven by strong uptake of J&J’s (JNJ - Free Report) subcutaneous Darzalex (Darzalex SC) in multiple myeloma patients, which was launched during the second quarter. However, royalties were hurt due to lower sales of matured partnered drugs like Rituxan Hycela and Herceptin Hylecta due to biosimilar competition.
Product sales, solely from the sale of bulk rHuPH20 to collaborators using the ENHANZE platform for drug development, decreased 69% to $9 million in the third quarter. In the prior-year quarter, the company had recorded a bulk sale to J&J.
Revenues under collaborative agreements were $32.3 million compared with $0.4 million in the prior-year quarter. The significant increase was due to the company’s recognition of expected milestone payments from Roche and argenx related to their pipeline progress.
Research and development (R&D) expenses declined 74.6% year over year to $7.7 million mainly due to discontinuation of oncology drug development efforts.
Selling, general and administrative (SG&A) expenses were $11.7 million, down 34.9% from the year-ago period. The decline was due to lower compensation and commercial-related expenses as a result of a restructuring initiatives announced last year.
The company repurchased its own common stock worth $58.9 million during the third quarter.
Business Developments
Halozyme’s collaboration partner, argenx, is expected to initiate a phase III study by the year end to evaluate efgartigimod SC, developed using Halozyme's ENHANZE technology. The study will evaluate the candidate as potential treatment for pemphigus (vulgaris and foliaceus), a group of autoimmune skin disorders. argenx has initiated a phase I study to evaluate subcutaneous ARGX-117 developed using ENHANZE technology. Moreover, argenx also expanded its collaboration agreement with Halozyme for exclusive access to ENHANZE drug delivery technology for three additional targets last month.
In September, Takeda’s subcutaneous formulation of Hyqvia received approval for label expansion in Europe to include adults, adolescents and children with an expanded range of secondary immunodeficiencies. J&J also filed a label expansion for Darzalex SC in the same month to include light chain amyloidosis.
Meanwhile, the company stated on its earnings call that six clinical studies are expected to be initiated by its partners in the rest of 2020.
2020 Guidance Raised
Halozyme raised its view for revenues and earnings for 2020. The company expects total revenues in 2020 to be between $250 million and $260 million compared with $230 million and $245 million previously expected. The guidance indicates year-over-year growth of 28-33%. The revenues guidance includes royalties of $80-85 million, revenues under collaboration of $115-120 million, and product sales of $52-57 million.
It expects earnings to be in the range of 80-85 cents per share. The company previously expected earnings to be in the range of 60-75 cents per share.
Increased guidance for 2020 indicates higher outlook for royalties and greater visibility on anticipated milestone revenues.
Halozyme Therapeutics, Inc. Price, Consensus and EPS Surprise
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Bigstock
Halozyme (HALO) Q3 Earnings Top, 2020 View Up, Stock Rises
Halozyme Therapeutics, Inc. (HALO - Free Report) reported third-quarter 2020 earnings of 25 cents per share, beating the Zacks Consensus Estimate of 20 cents. The company had reported a loss of 17 cents in the year-ago quarter.
Total revenues increased 41.3% year over year to $65.3 million primarily due to milestone payments from Roche (RHHBY - Free Report) and argenx (ARGX - Free Report) . The top line also beat the Zacks Consensus Estimate of $60 million.
Shares of Halozyme were up 7.7% in after-market trading on Nov 2, following the earnings release. The stock has gained 83.8% so far this year compared with the industry’s 1% increase.
Quarterly Highlights
Halozyme’s top line comprises product sales, royalties and revenues under collaborative agreements.
Royalty revenues were $23.9 million in the third quarter, up 44.1% from the year-ago quarter mainly driven by strong uptake of J&J’s (JNJ - Free Report) subcutaneous Darzalex (Darzalex SC) in multiple myeloma patients, which was launched during the second quarter. However, royalties were hurt due to lower sales of matured partnered drugs like Rituxan Hycela and Herceptin Hylecta due to biosimilar competition.
Product sales, solely from the sale of bulk rHuPH20 to collaborators using the ENHANZE platform for drug development, decreased 69% to $9 million in the third quarter. In the prior-year quarter, the company had recorded a bulk sale to J&J.
Revenues under collaborative agreements were $32.3 million compared with $0.4 million in the prior-year quarter. The significant increase was due to the company’s recognition of expected milestone payments from Roche and argenx related to their pipeline progress.
Research and development (R&D) expenses declined 74.6% year over year to $7.7 million mainly due to discontinuation of oncology drug development efforts.
Selling, general and administrative (SG&A) expenses were $11.7 million, down 34.9% from the year-ago period. The decline was due to lower compensation and commercial-related expenses as a result of a restructuring initiatives announced last year.
The company repurchased its own common stock worth $58.9 million during the third quarter.
Business Developments
Halozyme’s collaboration partner, argenx, is expected to initiate a phase III study by the year end to evaluate efgartigimod SC, developed using Halozyme's ENHANZE technology. The study will evaluate the candidate as potential treatment for pemphigus (vulgaris and foliaceus), a group of autoimmune skin disorders. argenx has initiated a phase I study to evaluate subcutaneous ARGX-117 developed using ENHANZE technology. Moreover, argenx also expanded its collaboration agreement with Halozyme for exclusive access to ENHANZE drug delivery technology for three additional targets last month.
In September, Takeda’s subcutaneous formulation of Hyqvia received approval for label expansion in Europe to include adults, adolescents and children with an expanded range of secondary immunodeficiencies. J&J also filed a label expansion for Darzalex SC in the same month to include light chain amyloidosis.
Meanwhile, the company stated on its earnings call that six clinical studies are expected to be initiated by its partners in the rest of 2020.
2020 Guidance Raised
Halozyme raised its view for revenues and earnings for 2020. The company expects total revenues in 2020 to be between $250 million and $260 million compared with $230 million and $245 million previously expected. The guidance indicates year-over-year growth of 28-33%. The revenues guidance includes royalties of $80-85 million, revenues under collaboration of $115-120 million, and product sales of $52-57 million.
It expects earnings to be in the range of 80-85 cents per share. The company previously expected earnings to be in the range of 60-75 cents per share.
Increased guidance for 2020 indicates higher outlook for royalties and greater visibility on anticipated milestone revenues.
Halozyme Therapeutics, Inc. Price, Consensus and EPS Surprise
Halozyme Therapeutics, Inc. price-consensus-eps-surprise-chart | Halozyme Therapeutics, Inc. Quote
Zacks Rank
Halozyme currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>